---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-055999"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:36:59.944299+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q1 net loss $6.2M; advances Alzheimer's and dry AMD trials

## Summary
- Net loss $6.2M ($0.21 per share) vs $3.8M ($0.17) in Q1 2022.
- Cash $38.8M; runway into H2 2024; $35M equity agreement with Lincoln Park Capital.
- Completed enrollment in Phase 2 SEQUEL (Alzheimer's); topline data expected Q2 2023.
- FDA cleared Phase 2 START (540 patients) for early AD and Phase 2 MAGNIFY for dry AMD.
- Hired John Doyle as CFO effective May 1, 2023.

## SEC filing metadata
- accession: 0001104659-23-055999
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/0001104659-23-055999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/tm2314531d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-055999
- JSON: https://secwatch.observer/filing/0001104659-23-055999.json
- Plain text: https://secwatch.observer/filing/0001104659-23-055999.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2023 results: net income a net loss of $6.2 million, EPS $(0.21) per basic and diluted share.
  - Period: first quarter ended March 31, 2023
  - Net income: a net loss of $6.2 million
  - EPS: $(0.21) per basic and diluted share
  - Result: reported results
  source text: The Company reported a net loss of $6.2 million, or $(0.21) per basic and diluted share for the first quarter ended March 31, 2023, compared to a net loss of $3.8 million or $(0.17) per basic and diluted share during the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/0001104659-23-055999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.